Lonza has completed a $15 million, multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity at its Tampa, FL site. The expansion will enable more integrated services for customers across early-stage product development, clinical trial material manufacture and commercialization of innovative drug products. The Tampa site is part of Lonza’s global network for the design, development and manufacturing of drug substances and intermediates, particle enginee...